SELLAS Life Sciences Provides Galinpepimut-S and Nelipepimut-S Program Update
February 12, 2019 08:45 ET
|
SELLAS Life Sciences Group
Dr. Richard Maziarz and Dr. Roisin O'Cearbhaill Named Co-Principal Investigators for Galinpepimut-S (GPS) – Pembrolizumab Phase 1/2 Basket Trial Immune Response Data from the Phase 2b Nelipepimut-S...
SELLAS Life Sciences to Present at the 2019 BIO CEO & Investor Conference
January 31, 2019 08:30 ET
|
SELLAS Life Sciences Group
NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...
SELLAS Life Sciences Provides Update on Late-Stage Immunotherapy Clinical Development Pipeline
January 08, 2019 08:30 ET
|
SELLAS Life Sciences Group
Aligned with FDA on Phase 3 Registration-Enabling Trial for Galinpepimut-S (GPS) in Acute Myeloid Leukemia; Trial Expected to Start in Q2 2019 Enrollment of Phase 1/2 Basket Trial of GPS plus...
SELLAS Life Sciences Announces Additional Positive Triple Negative Breast Cancer (TNBC) Subgroup Data from Phase 2b Study of Nelipepimut-S Plus Trastuzumab at the 2018 San Antonio Breast Cancer Symposium
December 06, 2018 08:30 ET
|
SELLAS Life Sciences Group
Clinically Meaningful and Statistically Significant Decrease in the Frequency of Clinically Detected Recurrences in the TNBC Cohort Treated with Nelipepimut-S plus Trastuzumab (p=0.004) Specific...
SELLAS to Present Further Correlative Data from Phase 2b Trial of NeuVax + Herceptin® at the 2018 San Antonio Breast Cancer Symposium
November 30, 2018 08:30 ET
|
SELLAS Life Sciences Group
NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...
SELLAS Life Sciences Announces Expedited Development Path for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Following Feedback from FDA
November 28, 2018 08:30 ET
|
SELLAS Life Sciences Group
Agreement on new open-label randomized registrational Phase 3 study in patients in second complete remission (CR2) poised to reduce sample size, time to primary endpoint and costs Fast-Track and...
SELLAS Life Sciences Announces Completion of Enrollment in Phase 2 Randomized Controlled Clinical Study of Nelipepimut-S Plus Trastuzumab in High-risk, High-expression HER2 Breast Cancer Patients
November 26, 2018 08:30 ET
|
SELLAS Life Sciences Group
Data Expected in Fourth Quarter of 2019 Second Clinical Study of Nelipepimut-S Plus Trastuzumab After Recently Announced Positive Phase 2b Study in Low-expression HER2 or Triple Negative Breast...
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2018 Financial Results
November 15, 2018 07:30 ET
|
SELLAS Life Sciences Group
Conference call today at 8:00 a.m. ET NEW YORK, Nov. 15, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical...
SELLAS Life Sciences Announces Additional Data Showing Consistent Clinical Effect Across HLA Allele Subgroups in Triple Negative Breast Cancer (TNBC) Patients Treated with Nelipepimut-S Plus Trastuzumab Presented at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
November 09, 2018 08:55 ET
|
SELLAS Life Sciences Group
Final data from Phase 2b clinical trial of nelipepimut-S (NeuVax™) in combination with trastuzumab (Herceptin®) were previously presented at the European Society for Medical Oncology (ESMO) 2018...
SELLAS Life Sciences Announces Settlement of Counterclaims Against JGB (Cayman) Newton, Ltd. for $6.6 Million Payment by JGB
November 09, 2018 08:30 ET
|
SELLAS Life Sciences Group
Follows Dismissal by Court of All Claims Against SELLASDebenture and All Security Interests Held by JGB Terminated NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc....